GB2305174A - Chemical process - Google Patents

Chemical process Download PDF

Info

Publication number
GB2305174A
GB2305174A GB9619011A GB9619011A GB2305174A GB 2305174 A GB2305174 A GB 2305174A GB 9619011 A GB9619011 A GB 9619011A GB 9619011 A GB9619011 A GB 9619011A GB 2305174 A GB2305174 A GB 2305174A
Authority
GB
United Kingdom
Prior art keywords
compound
formula
product
preparing
base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB9619011A
Other versions
GB9619011D0 (en
Inventor
Fraine Paul John De
Martin Charles Bowden
Patrick Mcneilly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syngenta Ltd
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9518897.5A external-priority patent/GB9518897D0/en
Priority claimed from GBGB9602622.4A external-priority patent/GB9602622D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of GB9619011D0 publication Critical patent/GB9619011D0/en
Publication of GB2305174A publication Critical patent/GB2305174A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C07C45/455—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation with carboxylic acids or their derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/255—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3

Abstract

6-Trifluoro-, 6-chlorodifluoro- and 6-difluoromethyl-2-hydroxypyridines are prepared by decarboxylating the corresponding nicotinic acid at a temperature above 190{C at normal atmospheric pressure. 6-Trifluoro-, 6-chlorodifluoro- and 6-difluoromethyl-2-hydroxy-nicotinic acids are novel compounds and are prepared by hydrolyzing the corresponding nicotinic acid ester or amide or the corresponding nitrile. The pyridines are useful chemical intermediates in the preparation of agricultural products. A process for the preparation of a compound of formula CF 2 XCOCH=CHOR 3 is also disclosed.

Description

CHEMICAL PROCESS This invention relates to a chemical process and more particularly to a novel process for preparing 6-trifluoro-, 6-chlorodifluoro- and 6-difluoromethyl-2-hydroxypyridines which are useful chemical intermediates in the manufacture of agricultural pesticides. The invention also relates to novel intermediates for preparing these pyridines and to a method for the preparation of the intermediates.
The compound 6-trifluoromethyl-2-hydroxypyridine (and its tautomer 6-trifluoromethylpyndone), is known as an intermediate in the manufacture of various agricultural pesticides, such as herbicides and insecticides. Hitherto, it has been prepared, for example, by the trifluoromethylation of 2-hydroxypyridine with bromotrifluoromethane (EP-AO206951) and by the hydrolysis of 6-trifluoromethyl-2-chloropyridine (US 3787420, US 3711486, US 3705170, US 3682936, US 3609158).
It is also known that halopyridinecarboxylic acids lose carbon dioxide at elevated temperatures to give halopyridines (The Chemistry of Heterocyclic Compounds : Pyridine and its Derivatives, Part Two, [1961], E. Klingsberg (editor), 342-343).
According to the present invention, there is provided a process for preparing a compound of formula (I)l wherein X is H, F or C1, which comprises heating a compound of formula (11) wherein X is as defined above at a temperature above 1900C at normal atmospheric pressure.
The compound (I) may exist in the form of its pyridone tautomer, or in admixture with it. Any reference herein to compound (I) should be taken as a reference to either tautomeric form or mixtures thereof in any proportion.
In the invention process, decarboxylation of compound (11) takes place at a temperature above 190"C either as a melt or in a high boiling, inert organic solvent. The temperature will usually be in the range of 195"C to 300"C, for example, 200"C to 260"C, and typically from 230"C to 250"C. If an organic solvent is used, the solvent will have a boiling point above the decarboxylation temperature and will be inert, ie. unreactive, towards compound (I1) and the decarboxylated product. Typically, the solvent will be an aromatic or heteroaromatic See Chemical Formulae at the end of this specification for chemical structures.
compound from which the end product can be conveniently separated at the end of the decarboxylation process, for instance by dissolution of a salt of it in water. Where separation of the end product is by dissolution of a salt (eg an alkali metal salt) in water, the solvent will need to be insoluble or only slightly soluble in water. Other methods of separation, for example, by evaporation of the solvent, may also be used where convenient. Examples of suitable solvents are N-methyl- pyrrolidone (boiling point (bp) 202"C), N-N-diethylaniline (bp 217"C), l,3-dimethylimidazolidinone (bp 222260C) and diphenylether (bp. 253"C). A preferred solvent is quinoline (bp 240"C).
A catalyst, for example a transition metal catalyst such as copper, may be used to assist reaction.
In a typical process, the compound (11) is added with stirring to a pre-warmed solvent and any water present distilled off as the temperature is raised above 100 C. When quinoline is used as the solvent, the reaction temperature is raised, for example, to about 235"C and held at that temperature for several hours, for instance around 4 hours, according to batch size, catalyst usage, acceptable degree of decarboxylation, etc. When decarboxylation is as complete as desired, the temperature is reduced to near ambient temperature, and a further solvent, such as toluene, added, followed by aqueous caustic solution.
Any particulate material is filtered out and the aqueous layer separated. The product can then be isolated as a precipitated solid by acidification of the aqueous layer. Keeping the pH of the acidified layer between 5.5 and 6.5 during isolation of the product has been found to give an advantage in terms of product quality.
Where compound (I1) is 6-chlorodifluoro- or 6-difluoromethyl-2-hydroxynicotinic acid, i.e. where X is H or C1, the decarboxylation process is best performed in the absence of a solvents The starting material, compound (It), is a novel compound, as is its pyridone tautomer and any mixtures thereof. This compound forms another aspect of the present invention together with a process for its preparation.
Accordingly, as part of this invention, there is also provided a process for the preparation of a compound of formula (n) which comprises treating a compound of the formula (E) wherein Y is a carboxylic acid ester, amide or cyano group, with an inorganic acid or base and, where a base is used, acidifying the metal salt of the product so formed.
In the compound (m), Y is suitably a carboxylic acid ester group COOR wherein R is a lower alkyl group, an amide group CONR1R2 wherein Rl and R2 are independently hydrogen or lower alkyl, or a cyano group. Lower alkyl is used herein to include Cl alkyl, conveniently C alkyl, for example methyl and ethyl. Typically, R is ethyl and Rl and R2 are both hydrogen.
The compound (In) is conveniently hydrolysed to the nicotinic acid by refluxing in concentrated hydrochloric acid or in sulphuric acid. Alternatively, it may be refluxed in an alkali metal hydroxide, for instance, sodium or potassium hydroxide, followed by acidification of the alkali metal salt of the nicotinic acid so formed. The reaction time will depend on batch size and other factors, but 2 to 6 hours will usually be sufficient.
When hydrochloric acid is used, hydrogen chloride is conveniently removed at the end of reaction by distillation and the product isolated by solvent extraction or filtration. When sulphuric acid or a base is used, the product is isolated by filtration, after acidification in the latter case.
Therefore, in another aspect of the present invention there is provided a process for preparing a compound of formula (I) wherein X is H, F or C1, which comprises the steps: (a) preparing a compound (11) wherein X is as defined above, by treating a compound of the formula (X as previously defined with an inorganic acid or base, and where a base is used, acidifying the metal salt of the product so formed; and (b) heating the product of (a) at a temperature above 1900C at normal atmospheric pressure.
The compound of formula (m) wherein X is F and a method for its preparation are known in the literature. R W Lang and P F Wenk describe the general method set out in Scheme A in Helv. Chim. Acta. 1988, 71(3), 596-601. This method can also be used to make the compound m wherein X is H or C1. Thus, in compounds (IV), (V), (VI), and (VII) in Scheme A, X is H, F or C1, R3 is lower alkyl as previously defined, for example, methyl, ethyl or n-butyl, and Y is as previously defined.
In the first stage of Scheme A, trifluoro-, chlorodifluoro or difluoroacetic anhydride (IV) optionally in a convenient solvent such as chloroform, is added gradually to a stirred mixture of the alkyl vinyl ether (V), pyridine and a compatible solvent, conveniently chloroform, maintaining the temperature between 0 and 200C. The reaction mixture is then stirred at 20-25 (z. When no further reaction takes place, the reaction mixture is quenched with water, the product extracted from the aqueous layer with a convenient solvent such as dichloromethane and the product (VI) isolated by evaporation of the solvent. As an alternative to the use of a separate solvent such as chloroform, additional quantities of an alkyl vinyl ether may be employed. Thus, the chloroform used may be replaced by an equal volume of an alkyl vinyl ether.This has advantages in terms of recovery and recycling of the alkyl vinyl ether solvent.
Although this stage of the process as described in the literature gives the product in an acceptable yield and purity under dilute concentrations, for example 2% w/v, at higher concentrations necessary for commercial production (eg. 20% w/v), lower yields are obtained and the product (VI) is of poorer quality and unstable. It has been found that this instability is associated with an excess of the acetic anhydride ('V). Thus, according to a further aspect of the present invention there is provided an improved process for the preparation of a compound of formula (VI) which comprises contacting an alkyl vinyl ether of formula (V) wherein R3 is lower alkyl with a stoichiometric amount of an acetic anhydride (IV) in a convenient solvent and in the presence of pyridine.
By stoichiometric amount of an acetic anhydride is meant approximately 1 mole of the acetic anhydride (IV) for each mole used of the alkyl vinyl ether (V).
The amount of pyridine may vary, for example, from 0.3 mole/mole to 1 mole/mole of the alkyl vinyl ether (V). Suitably, 1 mole of pyridine for each mole of (V) is used.
A convenient solvent is a chlorinated alkane, such as a chlorinated methane, for example chloroform or dichloromethane. The amount used is such that the process is carried out at a concentration of from 15% w/v to 25% wlv, typically 15-20% w/v, ie. 15-20g vinyl ether substrate per 100 ml of solvent.
The temperature of reaction is maintained below 30"C, preferably between 20"C to 25"C once mixing of the ingredients is complete.
The second stage of Scheme A is conveniently carried out by adding the compound (VII) wherein Y is as previously defined, to an alkali metal alkoxide dissolved in an alcohol, suitably sodium methoxide in methanol or sodium ethoxide in ethanol, with cooling to control the associated exotherm. Once the exotherm has subsided, the first stage product (VI) is added and the mixture heated under reflux. The reaction may be quenched with hydrochloric acid and the product mass extracted with a suitable solvent such as ethyl acetate. The solution is then dried and the solvent removed by evaporation. Alternatively, the reaction mixture is drowned into water, the methanol removed by distillation and the precipitated product filtered off and dried.
The addition of a second solvent, such as N,N4imethylformamide, to the alcohol allows the reaction to be carried out at higher concentrations, up to, for example, 20% wlv, avoiding solidification of the reaction mass.
Examples of the compound (VII) are cyanoacetamide, malonamide and ethyl malonate monoamide. Malonamide is particularly suitable. When an ester is used, ie. when Y in formula (V) is a carboxylic acid ester group, the value of Y in the compound (In) produced in the second stage of Scheme A may be the same or different depending on the choice of metal alkoxide used in the process. For instance, where ethyl malonate monoamide (VII, Y=COOEt) is used in conjunction with sodium methoxide, the compound (In) obtained may be in the form of the methyl ester (m, Y=COOMe).
Therefore, in yet another aspect of the present invention there is provided a process which comprises the steps: (i) preparing a compound of the formula (VI) as previously defined by contacting an alkyl vinyl ether of formula (V) as previously defined with a stoichiometric amount of an acetic anhydride (IV) as previously defined in a convenient solvent in the presence of pyridine; (ii) preparing a compound of the formula (m) as previously defined by reacting the product of (i) with a compound of formula (VII) as previously defined in the presence of an alkyl metal alkoxide in an alcohol solvent;; (iii) preparing a compound of formula (11) wherein X is H, F or C1 by treating the product of (ii) with an inorganic acid or base, and where a base is used, acidifying the metal salt of the product so formed; and (iv) heating the product of (iii) at a temperature above 190 C at normal atmospheric pressure to obtain a compound of formula (I) wherein X is H, F or C1.
The compound (m) wherein X is H and Y is as previously defined may also be prepared by the reduction of the corresponding compound (In) wherein X is C1, for example, in a suitable solvent in the presence of zinc dust. The reduction may be assisted by sonication in an ultra-sonic bath. The compound (11) wherein X is H may also be prepared either from a compound (m) wherein X is H by the method described earlier or by the reduction of the compound (11) wherein X is C1, for example, in a suitable solvent in the presence of zinc dust.
The following Examples illustrate the invention. Unless otherwise stated, magnesium sulphate was used to dry solutions, solutions were concentrated under reduced pressure, reactions involving water-sensitive reagents were performed under an atmosphere of nitrogen and solvents were dried before use, where appropriate.
EXAMPLE 1 Preparation of 2-hydroxy-6-trifluoromethylpyridine by decarboxylation of 2-hydroxyStrifluoronicotinic acid.
Quinoline (2949g, 96%, 21.92 mol) was charged to split-neck reaction flask fitted with a reflux condenser and thermometer and heated to 60"C by means of an isomantle.
2-HydroxyStrifluoromethylnicotinic acid obtained by the method of Example 11 (2710g, 83.6%, 10.94 mol) was charged to the flask and the solution heated to 235"C with agitation using a mechanical agitator. Above 100 C, water present in the nicotinic acid was distilled ~off. The reaction liquors were held for 4 hours at 235"C, decarboxylation being monitored by HPLC analysis of samples of the reaction liquors taken at intervals. The contents of the flask were then cooled to room temperature. Toluene (9600g, 99%) was charged to the flask, followed by caustic solution (1650g, 47%) and water (10500g).The liquors were agitated for 30 minutes at 3040 C and then passed through a filter to remove black particulate material.
The liquors were then allowed to settle before the lower aqueous layer was separated off.
Water (5200g) and caustic soda (826g, 47%) were added to the toluene layer and the mixture was agitated for 15 minutes, allowed to settle and the lower aqueous layer was again separated off. The combined aqueous layers were heated to 45-50"C and washed with toluene (7000g, 99%). The upper toluene layer was separated off and carbon Norit CN4' (88g) was charged to the aqueous layer. The liquors were agitated for 1 hour and then screened through a filter. Hydrochloric acid (4240g, 36%, 41.82 mol) was charged to the filtrates, precipitating the product. The liquors were stirred overnight at room temperature and then filtered. The solid was washed with 2 x lkg of water and deliquored before discharging. Yield 1489.3g at 100%wt (83.5% theory yield).
EXAMPLES 2-10 Further preparations of 2-hydroxy-itrifluoromethylpyridine by decarboxylation of 2-hydroxy-6-tiifluoronicotinlc acid.
In a similar manner to Example 1, the following Examples were carried out.
Eumpie Scale Concentration Solvent Conditions Yield No. (g nicotinic acid) (% wiv 2 5.1 None 2.5hr at 79 2500C 3 2 13 N-methyl- 6 hr at 9* pyrrolidone 206 C 4 2 50 N,N-diethyl- 4 hr at 3.5* aniline 217 C 5 2 50 Diphenyl 4 hr at 20* ether 259 C 6 1 50 Quinoline 4 hr at 100* 235 C with copper catalyst 7 1 50 Quinoline 4 hr at 100* 235 C 8 2 50 1,3-dimethyl 10 hr at 90* imidazol- 2250C idione 9 12 75 Quinoline 3 hr at 100* 200-205 C 10 9.7 75 Quinoline 3brat 74.9 2330C
* = 9b conversion EXAMPLE 11 Preparation of 2-hydroxy-6-trifluoromethylnicotinic acid by the hydrolysis of 2-hydroxy-6-trifluoromethylnicotinamide.
Water (7600kg) was charged to a split-neck reaction flask fitted with a reflux condenser, thermometer, and mechanical agitator. Sulphuric acid (1859g, 98%, 18.579 mol) was added dropwise to the stirred water followed by 2-hydroxy-6-trifluoromethylnicotinamide obtained by the method of Example 16 (1380g, 92.5%, 6.193 mol). The reaction liquors were heated to reflux (104 C) and held for 6 hours. A sample was taken for end of reaction analysis. The batch was cooled to room temperature and held for 1 hour before filtering the precipitate. The solid was washed with 2 x 1000g water. The solid was pulled free of liquors under vacuum before discharging.
Yield 1341.13g at 88.27% strength (1183.8g at 100%wt: 92.3% theory yield).
1H NMR(d6 acetone) 6:7.40(1H,d) 8.60(1H,d), 11.85(2H,br) ppm.
mp 160-162 C (effervescence).
EXAMPLES 12-15 Further preparations of 2-hydroxy-6-trifluoromethylnicotinic acid by the hydrolysis of a compound of the formula (In) where X is F.
In a similar manner to Example 11, the following Examples were carried out.
When hydrochloric acid was used instead of sulphuric acid, hydrogen chloride was removed by distillation at atmospheric pressure at the end of the reaction and the resulting solid product dried under vacuum.
example Y in Compound Scale Concentration Conditions Yield No. ("1) (gof (% w/v) III) 12 COOEt 18 26 3.5 hr reflux in HC1 84 13 CONH2 10 24 2 hr reflux in HC1 > 95 14 CONH2 5 16 2 hr reflux in c H2S04 87.3 15 CONH2 50 11.5 2 hr reflux in 88 followed by adjustment of Htol EXAMPLE 16 Preparation of 2-hydroxy-6-trifluoromethylnicotinamide.
A dry, nitrogen purged split-neck reaction flask was fitted with a mechanical stirrer, condenser, thermometer and dropping funnel. To the flask was added methanol (6282g) followed by a sodium methoxidelmethanol solution (1914g, 30%, 10.6 mol). Malonamide (772g, 98%, 7.41 mol) was charged and the reaction liquors agitated for 15 minutes.
(E)4Ethoxy-1,1,1-trifluoro-3-buten-2-one obtained by the method of Example 21 (1978g, 64.5%, 7.59 mol) was slowly run from the dropping funnel into the reaction flask. The liquors were slowly heated to reflux.
After 2 hours at reflux, the batch was sampled for end of reaction analysis. When the reaction was complete, water (1780g) was added and then HCl (687g, 36%, 6.77 mol) was run in slowly at 45"C. The pH was checked to be between pH 1 - 3. The reaction liquors were stirred overnight at room temperature.
The liquors were heated to reflux and then set for atmospheric distillation of methanol.
After distillation, water (9.38kg) was charged and the liquors cooled to 15 C to precipitate the product. The liquors were held at 15"C for 1 hour and then passed through a filter.
The solid was washed with 2 x 1000g water and pulled free of liquors. The solid was discharged giving 1292g of the title product as a 98.6% paste (1274g at 100% wt: 81.1% yield).
EXAMPLES 17-20 These Examples illustrate the preparation of a compound (Ill) where X is F and Y is CN, COOC2H5 or CONH2 from (E)-4-ethoxy-1,1,1-trifluoro-3-buten-2-one (compound (VI) where X is F) and a compound (VII) where Y is CN, COOC2H5 or CONH2. The method of preparation used was similiar to the one used in Example 16. The main differences were that sodium ethoxide and ethanol were used instead of sodium methoxide and methanol and the end product was extracted with ethyl acetate after quenching the reaction mass with hydrochloric acij The ethyl acetate solution was dried and the solvent removed by rotary evaporation.
Example Y in Compound Scale Concentration Conditions Yield No. (VII) (g of VI) (% w/v) % 17 CN 25 10 2 hr reflux 59 in ethanol 18 COOC2H5 10 4 2hrreflux 78 in ethanol 19 CONH2 10 20 N,N4imethyl- 62 formamide/- ethanol (4/1) 80OCft,r2br 20 CONH2 10 10 2hrreflux 80 in ethanol EXAMPLE 21 Preparation of (E)4ethoxy-l,l, -trifluoro-3-buten-2-one A dry, nitrogen purged 3-split-neck reaction flask was fitted with an overhead stirrer, dropping funnel and thermometer. Chloroform (9954g) was added to the flask and cooled to 10 C. Ethyl vinyl ether (1373g, 99%, 18.854 mol) was run slowly into the flask from the dropping funnel followed by pyridine (1505g, 99%, 18.854 mol). The solution was cooled to 5 C and trifluoroacetic anhydride (4000g, 99%, 18.854 mol) was added over 3.75 hours from the dropping funnel while maintaining the temperature below 20 C. After stirring for 30 minutes at 20-25 C, water (9370g) was added, stirring continued for another 30 minutes, and the reaction mixture then allowed to settle for 15 minutes. The upper aqueous layer and lower organic layer were separated and the organic layer washed with water (2 x 70û0g) and separated. Chloroform was distilled from the washed organic layer at ca 100 mbar at a temperature up to 40"C. The still residue was discharged giving the title product (3260g, 85%, 87.9% theory yield).
By comparison, similar experiments showed that using 2 mol trifluoroacetic anhydride 1 mol ethyl vinyl ether at a concentration of 20% w/v and 1.4 mol trifluoroacetic anhydride to 1 mol ethyl vinyl ether at a concentration of 16% w/v gave a product of low purity which decomposed.
EXAMPLE 22 Preparation of 6-chlorodifluoromethylpyrid-2-one.
Pyridine (24g) was added to a solution of ethyl vinyl ether (22g) in chloroform (75ml) under nitrogen keeping the temperature below 10 C. Chlorodifluoroacetic anhydride (75g) was added over 90 minutes keeping the temperature below 2O0C. The reaction mixture was stirred for 16 hours then quenched with water. The chloroform layer was washed with water, dried and concentrated to give (E)ethoxy-1,1,1-chiorodfiuorobuten-2one (50.2g, 91% yield) as an orange liquid; 'H NMR (270MHz): 1.43(3H,t), 4.12(2H,q), 5.89(1H,d), 7.90(1H,d) ppm.
Malonamide (27.5g) was added to a solution of sodium methoxide in methanol [prepared from sodium (8.7g) and methanol (300ml)]. After 15 minutes (E)ethoxy-l,l,lchlorodifluorobuten-2sne (50.2g) was added and the reaction mixture heated to reflux for 2 hours. After cooling the reaction mixture was concentrated then diluted with water, acidified with concentrated hydrochloric acid and the precipitate filtered off, washed with water and dried to give 6chlorodifluoromethyl-2-hydroxynicotinami (48.8g, 81% yield) as a white solid mp. 23S232 "C; 1H NMR (270MHz): 7.29(1H,brm), 8.03(1H,brs), 8.38(2H,d), 13.6(1H,brs) ppm.
6-Chlorodifluoromethyl-2-hydroxynicotinamide (48.5g) was heated in dilute sulphuric acid (36ml in 250ml water) for 12 hours. The reaction was concentrated to about half the volume and cooled in ice, and the precipitate filtered, washed with water and air dried to give schlorodinuoromethyl-2-bydroxynicotinic acid (48. lg, 98% yield) as a pale brown solid mp.13l-30C; 'H NMR (270MHz): o7.36(1H,d), 8.33(1H,d) ppm.
6-Chlorodifluoromethyl-2-hydroxynicotinic acid (l.lg) was heated to 250"C for 10 minutes until the effervescence had ceased. On cooling it was taken up in ethyl acetate and the organic phase washed with saturated sodium bicarbonate solution. The combined organic phase was dried, decolourised with activated charcoal and concentrated to give 6-chlorodifluoromethyl-pyrid-2-one (0.41g, 47% yield) as an off white solid; 1H NMR (270MHz): S 6.89(2H,m), 7.12(1H,t), 13.5(1H,brs) ppm.
EXAMPLE 23 Preparation of (E)thoxy- l,l,l-trifluoro-3-buten-2-one Pyridine (37.5g) and ethyl vinyl ether (159.9g) were charged to a dry 500ml flask and cooled to less than 50C with agitation. Trifluoroacetic anhydride (100g) was run into the flask from a dropping funnel over 2.5 hours maintaining a temperature of less than 150C. The reaction mixture was stirred for a further hour at 20-250C before washing with water (3 x 125ml). The separated organic layer was found to contain 71.86g of the title product on analysis (90.7% theory yield). Ethyl vinyl ether was removed by atmospheric distillation.
CHEMICAL FORMULAE (As in Description)

Claims (1)

  1. CLAIMS 1. A process for preparing a compound of formula (I):
    wherein X is H, F or C1, which comprises heating a compound of formula (11):
    wherein X is H, F or C1, at a temperature above 1900C at normal atmospheric pressure.
    2. A process according to claim 1 wherein the temperature is in the range of 195"C to 300"C.
    3. A process according to claim 1 or 2 wherein the compound of formula (11) is in molten form.
    4. A process according to claim 1 or 2 wherein the compound of formula (I1) is in a high boiling, inert organic solvents 5. A process for preparing a compound of formula (I) as defined in claim 1 which comprises the steps: (a) preparing a compound of formula (11) as defined in claim 1 by treating a compound of formula (In):
    wherein X is H, F or C1 and Y is a carboxylic acid ester, amide or cyano group, with an inorganic acid or base, and where a base is used, acidifying the metal salt of the product so formed; and (b) heating the product of (a) at a temperature above 1900C at normal atmospheric pressure.
    6. A process according to claim 5 wherein Y in the compound of formula (In) is a carboxylic acid ester group COOR wherein R is a lower alkyl group, an amide group CONR1R2 wherein Rl and R2 are independently hydrogen or lower alkyl, or a cyano group.
    7. A process for preparing a compound of formula (1) wherein X is F or C1, which comprises the steps: (i) preparing a compound of the formula CF2XCOCH=CHOR3, wherein X is H, F or C1 and R3 is lower alkyl, by contacting an alkyl vinyl ether of formula CH2=CHOR3 with a stoichiometric amount of an acetic anhydride (CF2XCO)2O in a convenient solvent in the presence of pyridine; (ii) preparing a compound of the formula (In):
    wherein X is F or Cl and Y is a carboxylic acid ester, arnide or cyano group by reacting the product of (i) with a compound of formula Y-CH2CONH2 in the presence of an alkyl metal alkoxide in an alcohol solvent; (iii) preparing a compound of formula (II)::
    wherein X is F or Cl, by treating the product of (ii) with an inorganic acid or base, and where a base is used, acidifying the metal salt of the product so formed; and (iv) heating the product of (iii) at a temperature above 190"C at normal atmospheric pressure.
    An improved process for the preparation of a compound of formula CF2XCOCH=CHOR3, wherein X is H, F or Cl and R3 is lower alkyl, which comprises contacting an alkyl vinyl ether of formula CH2=CHOR3 with a stoichiometric amount of an acetic anhydride (CF2XCO)20 in a convenient solvent and in the presence of pyridine.
    A compound of formula (II):
    wherein X is H, F or C1, or its tautomer of formula:
    or any mixture thereof.
    10. A process for the preparation of a compound of formula (U) as defined in claim 9, which comprises treating a compound of the formula (In):
    wherein X is H, F or C1 and Y is a carboxylic acid ester, amide or cyano group, with an inorganic acid or base and, where a base is used, acidifying the metal salt of the product so formed.
GB9619011A 1995-09-15 1996-09-11 Chemical process Withdrawn GB2305174A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9518897.5A GB9518897D0 (en) 1995-09-15 1995-09-15 Chemical process
GBGB9602622.4A GB9602622D0 (en) 1996-02-09 1996-02-09 Chemical process

Publications (2)

Publication Number Publication Date
GB9619011D0 GB9619011D0 (en) 1996-10-23
GB2305174A true GB2305174A (en) 1997-04-02

Family

ID=26307764

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9619011A Withdrawn GB2305174A (en) 1995-09-15 1996-09-11 Chemical process

Country Status (1)

Country Link
GB (1) GB2305174A (en)

Cited By (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000015615A1 (en) * 1998-09-15 2000-03-23 Syngenta Participations Ag Pyridine ketones useful as herbicides
WO2002002528A1 (en) * 2000-07-03 2002-01-10 Syngenta Limited Chemical process for the extraction of 2-hydroxy pyridine derivatives, 2-hydroxyquinoline, and 2-hydroxybenzothiazole
JP2002533443A (en) * 1998-12-23 2002-10-08 シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト Substituted pyridine herbicides
WO2003066558A2 (en) * 2002-02-08 2003-08-14 Solvay Fluor Und Derivate Gmbh Production of alkenones
US7371324B2 (en) 2000-07-03 2008-05-13 Syngenta Limited Chemical process
EP1987717A1 (en) * 2007-04-30 2008-11-05 Bayer CropScience AG Pyridon carboxamides, agents containing these but not impacting useful plants and method for their manufacture and application
EP1987718A1 (en) * 2007-04-30 2008-11-05 Bayer CropScience AG Utilisation of pyridine-2-oxy-3-carbon amides as safener
EP2360136A1 (en) * 2002-02-08 2011-08-24 Solvay Fluor GmbH Production of alkenones
US8080000B2 (en) 2004-04-21 2011-12-20 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat
US8088101B2 (en) 2004-04-21 2012-01-03 Acclarent, Inc. Devices, systems and methods for treating disorders of the ear, nose and throat
US8100933B2 (en) 2002-09-30 2012-01-24 Acclarent, Inc. Method for treating obstructed paranasal frontal sinuses
US8114062B2 (en) 2004-04-21 2012-02-14 Acclarent, Inc. Devices and methods for delivering therapeutic substances for the treatment of sinusitis and other disorders
US8114113B2 (en) 2005-09-23 2012-02-14 Acclarent, Inc. Multi-conduit balloon catheter
JP2012504153A (en) * 2008-09-30 2012-02-16 ソルヴェイ（ソシエテ アノニム） Method for the synthesis of halogenated cyclic compounds
US8118757B2 (en) 2007-04-30 2012-02-21 Acclarent, Inc. Methods and devices for ostium measurement
US8142422B2 (en) 2004-04-21 2012-03-27 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, nose and/or throat
US8146400B2 (en) 2004-04-21 2012-04-03 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US8172828B2 (en) 2004-04-21 2012-05-08 Acclarent, Inc. Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures
US8182432B2 (en) 2008-03-10 2012-05-22 Acclarent, Inc. Corewire design and construction for medical devices
US8190389B2 (en) 2006-05-17 2012-05-29 Acclarent, Inc. Adapter for attaching electromagnetic image guidance components to a medical device
WO2012085195A1 (en) 2010-12-23 2012-06-28 Solvay Sa Environmental friendly purification of an organic solution of etfbo
US8388642B2 (en) 2005-01-18 2013-03-05 Acclarent, Inc. Implantable devices and methods for treating sinusitis and other disorders
US8414473B2 (en) 2004-04-21 2013-04-09 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat
US8435290B2 (en) 2009-03-31 2013-05-07 Acclarent, Inc. System and method for treatment of non-ventilating middle ear by providing a gas pathway through the nasopharynx
US8439687B1 (en) 2006-12-29 2013-05-14 Acclarent, Inc. Apparatus and method for simulated insertion and positioning of guidewares and other interventional devices
US8485199B2 (en) 2007-05-08 2013-07-16 Acclarent, Inc. Methods and devices for protecting nasal turbinate during surgery
US8702626B1 (en) 2004-04-21 2014-04-22 Acclarent, Inc. Guidewires for performing image guided procedures
US8715169B2 (en) 2004-04-21 2014-05-06 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US8740929B2 (en) 2001-02-06 2014-06-03 Acclarent, Inc. Spacing device for releasing active substances in the paranasal sinus
US8747389B2 (en) 2004-04-21 2014-06-10 Acclarent, Inc. Systems for treating disorders of the ear, nose and throat
US8764729B2 (en) 2004-04-21 2014-07-01 Acclarent, Inc. Frontal sinus spacer
US8864787B2 (en) 2004-04-21 2014-10-21 Acclarent, Inc. Ethmoidotomy system and implantable spacer devices having therapeutic substance delivery capability for treatment of paranasal sinusitis
US8894614B2 (en) 2004-04-21 2014-11-25 Acclarent, Inc. Devices, systems and methods useable for treating frontal sinusitis
US8932276B1 (en) 2004-04-21 2015-01-13 Acclarent, Inc. Shapeable guide catheters and related methods
WO2015004040A1 (en) 2013-07-09 2015-01-15 Bayer Cropscience Ag Use of selected pyridone carboxamides or salts thereof as active substances against abiotic plant stress
US8951225B2 (en) 2005-06-10 2015-02-10 Acclarent, Inc. Catheters with non-removable guide members useable for treatment of sinusitis
US8979888B2 (en) 2008-07-30 2015-03-17 Acclarent, Inc. Paranasal ostium finder devices and methods
US9039680B2 (en) 2004-08-04 2015-05-26 Acclarent, Inc. Implantable devices and methods for delivering drugs and other substances to treat sinusitis and other disorders
US9072626B2 (en) 2009-03-31 2015-07-07 Acclarent, Inc. System and method for treatment of non-ventilating middle ear by providing a gas pathway through the nasopharynx
US9089258B2 (en) 2004-04-21 2015-07-28 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US9101384B2 (en) 2004-04-21 2015-08-11 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, Nose and/or throat
US9107574B2 (en) 2004-04-21 2015-08-18 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US9155492B2 (en) 2010-09-24 2015-10-13 Acclarent, Inc. Sinus illumination lightwire device
US9265407B2 (en) 2004-04-21 2016-02-23 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US9351750B2 (en) 2004-04-21 2016-05-31 Acclarent, Inc. Devices and methods for treating maxillary sinus disease
WO2016096942A1 (en) 2014-12-18 2016-06-23 Bayer Cropscience Aktiengesellschaft Use of selected pyridone carboxamides or salts thereof as active substances against abiotic plant stress
US9399121B2 (en) 2004-04-21 2016-07-26 Acclarent, Inc. Systems and methods for transnasal dilation of passageways in the ear, nose or throat
US9433437B2 (en) 2013-03-15 2016-09-06 Acclarent, Inc. Apparatus and method for treatment of ethmoid sinusitis
US9468362B2 (en) 2004-04-21 2016-10-18 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US9629684B2 (en) 2013-03-15 2017-04-25 Acclarent, Inc. Apparatus and method for treatment of ethmoid sinusitis
US9820688B2 (en) 2006-09-15 2017-11-21 Acclarent, Inc. Sinus illumination lightwire device
US10188413B1 (en) 2004-04-21 2019-01-29 Acclarent, Inc. Deflectable guide catheters and related methods
US10206821B2 (en) 2007-12-20 2019-02-19 Acclarent, Inc. Eustachian tube dilation balloon with ventilation path
US10349971B2 (en) 2011-06-29 2019-07-16 CARDINAL HEALTH SWITZERLAND 515 GmbH System and method for dilating and adjusting flexibility in a guiding device
US10524814B2 (en) 2009-03-20 2020-01-07 Acclarent, Inc. Guide system with suction
US11065061B2 (en) 2004-04-21 2021-07-20 Acclarent, Inc. Systems and methods for performing image guided procedures within the ear, nose, throat and paranasal sinuses
US11529502B2 (en) 2004-04-21 2022-12-20 Acclarent, Inc. Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures

Cited By (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6498125B2 (en) 1998-09-15 2002-12-24 Syngenta Participations Ag Pyridine ketones useful as herbicides
WO2000015615A1 (en) * 1998-09-15 2000-03-23 Syngenta Participations Ag Pyridine ketones useful as herbicides
JP2002533443A (en) * 1998-12-23 2002-10-08 シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト Substituted pyridine herbicides
US7371324B2 (en) 2000-07-03 2008-05-13 Syngenta Limited Chemical process
WO2002002528A1 (en) * 2000-07-03 2002-01-10 Syngenta Limited Chemical process for the extraction of 2-hydroxy pyridine derivatives, 2-hydroxyquinoline, and 2-hydroxybenzothiazole
CN101525315B (en) * 2000-07-03 2013-12-25 杜邦公司 Chemical process for extraction of 2-hydroxy pyridine derivatives, 2-hydroxyquinoline, and 2-hydroxybenzothiazole
CN100494176C (en) * 2000-07-03 2009-06-03 辛根塔有限公司 Method for extracting alkali metals or calcium salt of halogen or haloalkyl substituted 2-hydroxy pyridine, 2-hydroxyquinoline, and 2-hydroxybenzothiazole
JP2004502675A (en) * 2000-07-03 2004-01-29 シンジェンタ　リミテッド Chemical extraction method of 2-hydroxypyridine derivative, 2-hydroxyquinoline and 2-hydroxybenzothiazole
US7186839B2 (en) 2000-07-03 2007-03-06 Syngenta Limited Chemical process for the extraction of 2-hydroxy pyridine derivatives, 2-hydroxyquinoline, and 2-hydroxybenzothiazole
KR100788925B1 (en) 2000-07-03 2007-12-27 신젠타 리미티드 Chemical process for the extraction of 2-hydroxy pyridine derivatives, 2-hydroxyquinoline, and 2-hydroxybenzothiazole
US8740929B2 (en) 2001-02-06 2014-06-03 Acclarent, Inc. Spacing device for releasing active substances in the paranasal sinus
WO2003066558A3 (en) * 2002-02-08 2003-12-31 Solvay Fluor & Derivate Production of alkenones
CN1330622C (en) * 2002-02-08 2007-08-08 索尔微氟及衍生物有限公司 Production of alkenones
US7057079B2 (en) 2002-02-08 2006-06-06 Solvay Fluor Und Derivate Gmbh Method of synthesizing alkenone compounds
WO2003066558A2 (en) * 2002-02-08 2003-08-14 Solvay Fluor Und Derivate Gmbh Production of alkenones
EP2360136A1 (en) * 2002-02-08 2011-08-24 Solvay Fluor GmbH Production of alkenones
US8764786B2 (en) 2002-09-30 2014-07-01 Acclarent, Inc. Balloon catheters and methods for treating paranasal sinuses
US9457175B2 (en) 2002-09-30 2016-10-04 Acclarent, Inc. Balloon catheters and methods for treating paranasal sinuses
US8100933B2 (en) 2002-09-30 2012-01-24 Acclarent, Inc. Method for treating obstructed paranasal frontal sinuses
US8317816B2 (en) 2002-09-30 2012-11-27 Acclarent, Inc. Balloon catheters and methods for treating paranasal sinuses
US8715169B2 (en) 2004-04-21 2014-05-06 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US8864787B2 (en) 2004-04-21 2014-10-21 Acclarent, Inc. Ethmoidotomy system and implantable spacer devices having therapeutic substance delivery capability for treatment of paranasal sinusitis
US8090433B2 (en) 2004-04-21 2012-01-03 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat
US8080000B2 (en) 2004-04-21 2011-12-20 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat
US8114062B2 (en) 2004-04-21 2012-02-14 Acclarent, Inc. Devices and methods for delivering therapeutic substances for the treatment of sinusitis and other disorders
US11065061B2 (en) 2004-04-21 2021-07-20 Acclarent, Inc. Systems and methods for performing image guided procedures within the ear, nose, throat and paranasal sinuses
US11019989B2 (en) 2004-04-21 2021-06-01 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat
US11020136B2 (en) 2004-04-21 2021-06-01 Acclarent, Inc. Deflectable guide catheters and related methods
US8123722B2 (en) 2004-04-21 2012-02-28 Acclarent, Inc. Devices, systems and methods for treating disorders of the ear, nose and throat
US8142422B2 (en) 2004-04-21 2012-03-27 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, nose and/or throat
US8146400B2 (en) 2004-04-21 2012-04-03 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US8172828B2 (en) 2004-04-21 2012-05-08 Acclarent, Inc. Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures
US10874838B2 (en) 2004-04-21 2020-12-29 Acclarent, Inc. Systems and methods for transnasal dilation of passageways in the ear, nose or throat
US10856727B2 (en) 2004-04-21 2020-12-08 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US9399121B2 (en) 2004-04-21 2016-07-26 Acclarent, Inc. Systems and methods for transnasal dilation of passageways in the ear, nose or throat
US11202644B2 (en) 2004-04-21 2021-12-21 Acclarent, Inc. Shapeable guide catheters and related methods
US9468362B2 (en) 2004-04-21 2016-10-18 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US8414473B2 (en) 2004-04-21 2013-04-09 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat
US8425457B2 (en) 2004-04-21 2013-04-23 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitus and other disorder of the ears, nose and/or throat
US10806477B2 (en) 2004-04-21 2020-10-20 Acclarent, Inc. Systems and methods for transnasal dilation of passageways in the ear, nose or throat
US10779752B2 (en) 2004-04-21 2020-09-22 Acclarent, Inc. Guidewires for performing image guided procedures
US10702295B2 (en) 2004-04-21 2020-07-07 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat
US10695080B2 (en) 2004-04-21 2020-06-30 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, nose and/or throat
US11511090B2 (en) 2004-04-21 2022-11-29 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US8702626B1 (en) 2004-04-21 2014-04-22 Acclarent, Inc. Guidewires for performing image guided procedures
US11529502B2 (en) 2004-04-21 2022-12-20 Acclarent, Inc. Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures
US8721591B2 (en) 2004-04-21 2014-05-13 Acclarent, Inc. Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures
US11589742B2 (en) 2004-04-21 2023-02-28 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat
US8747389B2 (en) 2004-04-21 2014-06-10 Acclarent, Inc. Systems for treating disorders of the ear, nose and throat
US8764729B2 (en) 2004-04-21 2014-07-01 Acclarent, Inc. Frontal sinus spacer
US11864725B2 (en) 2004-04-21 2024-01-09 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, nose and/or throat
US8764709B2 (en) 2004-04-21 2014-07-01 Acclarent, Inc. Devices, systems and methods for treating disorders of the ear, nose and throat
US8764726B2 (en) 2004-04-21 2014-07-01 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US8777926B2 (en) 2004-04-21 2014-07-15 Acclarent, Inc. Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasel or paranasal structures
US8828041B2 (en) 2004-04-21 2014-09-09 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US8852143B2 (en) 2004-04-21 2014-10-07 Acclarent, Inc. Devices, systems and methods for treating disorders of the ear, nose and throat
US8858586B2 (en) 2004-04-21 2014-10-14 Acclarent, Inc. Methods for enlarging ostia of paranasal sinuses
US8088101B2 (en) 2004-04-21 2012-01-03 Acclarent, Inc. Devices, systems and methods for treating disorders of the ear, nose and throat
US8870893B2 (en) 2004-04-21 2014-10-28 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, nose and/or throat
US8894614B2 (en) 2004-04-21 2014-11-25 Acclarent, Inc. Devices, systems and methods useable for treating frontal sinusitis
US10631756B2 (en) 2004-04-21 2020-04-28 Acclarent, Inc. Guidewires for performing image guided procedures
US8905922B2 (en) 2004-04-21 2014-12-09 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, nose and/or throat
US8932276B1 (en) 2004-04-21 2015-01-13 Acclarent, Inc. Shapeable guide catheters and related methods
US10500380B2 (en) 2004-04-21 2019-12-10 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US8945088B2 (en) 2004-04-21 2015-02-03 Acclarent, Inc. Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures
US9370649B2 (en) 2004-04-21 2016-06-21 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US8961398B2 (en) 2004-04-21 2015-02-24 Acclarent, Inc. Methods and apparatus for treating disorders of the ear, nose and throat
US8961495B2 (en) 2004-04-21 2015-02-24 Acclarent, Inc. Devices, systems and methods for treating disorders of the ear, nose and throat
US10492810B2 (en) 2004-04-21 2019-12-03 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, nose and/or throat
US10441758B2 (en) 2004-04-21 2019-10-15 Acclarent, Inc. Frontal sinus spacer
US10188413B1 (en) 2004-04-21 2019-01-29 Acclarent, Inc. Deflectable guide catheters and related methods
US9351750B2 (en) 2004-04-21 2016-05-31 Acclarent, Inc. Devices and methods for treating maxillary sinus disease
US9265407B2 (en) 2004-04-21 2016-02-23 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US11957318B2 (en) 2004-04-21 2024-04-16 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat
US9241834B2 (en) 2004-04-21 2016-01-26 Acclarent, Inc. Devices, systems and methods for treating disorders of the ear, nose and throat
US9055965B2 (en) 2004-04-21 2015-06-16 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US10098652B2 (en) 2004-04-21 2018-10-16 Acclarent, Inc. Systems and methods for transnasal dilation of passageways in the ear, nose or throat
US9220879B2 (en) 2004-04-21 2015-12-29 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US9089258B2 (en) 2004-04-21 2015-07-28 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US9101384B2 (en) 2004-04-21 2015-08-11 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, Nose and/or throat
US10034682B2 (en) 2004-04-21 2018-07-31 Acclarent, Inc. Devices, systems and methods useable for treating frontal sinusitis
US9107574B2 (en) 2004-04-21 2015-08-18 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US9826999B2 (en) 2004-04-21 2017-11-28 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat
US9167961B2 (en) 2004-04-21 2015-10-27 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat
US9649477B2 (en) 2004-04-21 2017-05-16 Acclarent, Inc. Frontal sinus spacer
US9610428B2 (en) 2004-04-21 2017-04-04 Acclarent, Inc. Devices, systems and methods useable for treating frontal sinusitis
US9554691B2 (en) 2004-04-21 2017-01-31 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US9084876B2 (en) 2004-08-04 2015-07-21 Acclarent, Inc. Implantable devices and methods for delivering drugs and other substances to treat sinusitis and other disorders
US9039657B2 (en) 2004-08-04 2015-05-26 Acclarent, Inc. Implantable devices and methods for delivering drugs and other substances to treat sinusitis and other disorders
US9039680B2 (en) 2004-08-04 2015-05-26 Acclarent, Inc. Implantable devices and methods for delivering drugs and other substances to treat sinusitis and other disorders
US9308361B2 (en) 2005-01-18 2016-04-12 Acclarent, Inc. Implantable devices and methods for treating sinusitis and other disorders
US8388642B2 (en) 2005-01-18 2013-03-05 Acclarent, Inc. Implantable devices and methods for treating sinusitis and other disorders
US10124154B2 (en) 2005-06-10 2018-11-13 Acclarent, Inc. Catheters with non-removable guide members useable for treatment of sinusitis
US8951225B2 (en) 2005-06-10 2015-02-10 Acclarent, Inc. Catheters with non-removable guide members useable for treatment of sinusitis
US10842978B2 (en) 2005-06-10 2020-11-24 Acclarent, Inc. Catheters with non-removable guide members useable for treatment of sinusitis
US9050440B2 (en) 2005-09-23 2015-06-09 Acclarent, Inc. Multi-conduit balloon catheter
US8114113B2 (en) 2005-09-23 2012-02-14 Acclarent, Inc. Multi-conduit balloon catheter
US10639457B2 (en) 2005-09-23 2020-05-05 Acclarent, Inc. Multi-conduit balloon catheter
US9999752B2 (en) 2005-09-23 2018-06-19 Acclarent, Inc. Multi-conduit balloon catheter
US8968269B2 (en) 2005-09-23 2015-03-03 Acclarent, Inc. Multi-conduit balloon catheter
US9198736B2 (en) 2006-05-17 2015-12-01 Acclarent, Inc. Adapter for attaching electromagnetic image guidance components to a medical device
US9629656B2 (en) 2006-05-17 2017-04-25 Acclarent, Inc. Adapter for attaching electromagnetic image guidance components to a medical device
US8190389B2 (en) 2006-05-17 2012-05-29 Acclarent, Inc. Adapter for attaching electromagnetic image guidance components to a medical device
US9603506B2 (en) 2006-09-15 2017-03-28 Acclarent, Inc. Methods and devices for facilitating visualization in a surgical environment
US9820688B2 (en) 2006-09-15 2017-11-21 Acclarent, Inc. Sinus illumination lightwire device
US10716629B2 (en) 2006-09-15 2020-07-21 Acclarent, Inc. Methods and devices for facilitating visualization in a surgical environment
US9572480B2 (en) 2006-09-15 2017-02-21 Acclarent, Inc. Methods and devices for facilitating visualization in a surgical environment
US9179823B2 (en) 2006-09-15 2015-11-10 Acclarent, Inc. Methods and devices for facilitating visualization in a surgical environment
US8439687B1 (en) 2006-12-29 2013-05-14 Acclarent, Inc. Apparatus and method for simulated insertion and positioning of guidewares and other interventional devices
US9615775B2 (en) 2007-04-30 2017-04-11 Acclarent, Inc. Methods and devices for ostium measurements
EA020453B1 (en) * 2007-04-30 2014-11-28 Байер Кропсайенс Аг Pyridonecarboxamides and use thereof, crop protection agents, a method for protecting useful plants against phytotoxic side effects of agrochemicals, a method for the selective control of harmful plants in crops of useful plants
EP1987717A1 (en) * 2007-04-30 2008-11-05 Bayer CropScience AG Pyridon carboxamides, agents containing these but not impacting useful plants and method for their manufacture and application
EP1987718A1 (en) * 2007-04-30 2008-11-05 Bayer CropScience AG Utilisation of pyridine-2-oxy-3-carbon amides as safener
WO2008131861A1 (en) * 2007-04-30 2008-11-06 Bayer Cropscience Ag Use of pyridine-2-oxy-3-carbonamides as safeners
US9102623B2 (en) 2007-04-30 2015-08-11 Bayer Cropscience Ag Pyridinecarboxamides, useful-plant-protecting composition comprising them and processes for their preparation and their use
JP2010524985A (en) * 2007-04-30 2010-07-22 バイエル・クロツプサイエンス・アクチエンゲゼルシヤフト Pyridonecarboxamide, crop protection agent containing the same, method for producing the same and use thereof
KR101527981B1 (en) * 2007-04-30 2015-06-10 바이엘 인텔렉쳐 프로퍼티 게엠베하 Pyridonecarboxamides, crop protection agents containing the same, method for production and use thereof
WO2008131860A2 (en) * 2007-04-30 2008-11-06 Bayer Cropscience Ag Pyridonecarboxamides crop protection agents containing the same method for production and use thereof
WO2008131860A3 (en) * 2007-04-30 2009-09-03 Bayer Cropscience Ag Pyridonecarboxamides crop protection agents containing the same method for production and use thereof
US8118757B2 (en) 2007-04-30 2012-02-21 Acclarent, Inc. Methods and devices for ostium measurement
US8485199B2 (en) 2007-05-08 2013-07-16 Acclarent, Inc. Methods and devices for protecting nasal turbinate during surgery
US9463068B2 (en) 2007-05-08 2016-10-11 Acclarent, Inc. Methods and devices for protecting nasal turbinates
US11850120B2 (en) 2007-12-20 2023-12-26 Acclarent, Inc. Eustachian tube dilation balloon with ventilation path
US10206821B2 (en) 2007-12-20 2019-02-19 Acclarent, Inc. Eustachian tube dilation balloon with ventilation path
US11311419B2 (en) 2007-12-20 2022-04-26 Acclarent, Inc. Eustachian tube dilation balloon with ventilation path
US8182432B2 (en) 2008-03-10 2012-05-22 Acclarent, Inc. Corewire design and construction for medical devices
US9861793B2 (en) 2008-03-10 2018-01-09 Acclarent, Inc. Corewire design and construction for medical devices
US9750401B2 (en) 2008-07-30 2017-09-05 Acclarent, Inc. Paranasal ostium finder devices and methods
US8979888B2 (en) 2008-07-30 2015-03-17 Acclarent, Inc. Paranasal ostium finder devices and methods
US11116392B2 (en) 2008-07-30 2021-09-14 Acclarent, Inc. Paranasal ostium finder devices and methods
US10271719B2 (en) 2008-07-30 2019-04-30 Acclarent, Inc. Paranasal ostium finder devices and methods
JP2012504153A (en) * 2008-09-30 2012-02-16 ソルヴェイ（ソシエテ アノニム） Method for the synthesis of halogenated cyclic compounds
US8981115B2 (en) 2008-09-30 2015-03-17 Solvay Sa Process for the synthesis of halogenated cyclic compounds
US8431710B2 (en) 2008-09-30 2013-04-30 Solvay Sa Process for the synthesis of halogenated cyclic compounds
JP2015227339A (en) * 2008-09-30 2015-12-17 ソルヴェイ（ソシエテ アノニム） Process for synthesis of halogenated cyclic compounds
JP2018058869A (en) * 2008-09-30 2018-04-12 ソルヴェイ（ソシエテ アノニム） Method for synthesizing halogenated cyclic compound
JP2022028792A (en) * 2008-09-30 2022-02-16 ソルヴェイ（ソシエテ アノニム） Process for synthesis of halogenated cyclic compounds
US10524814B2 (en) 2009-03-20 2020-01-07 Acclarent, Inc. Guide system with suction
US11207087B2 (en) 2009-03-20 2021-12-28 Acclarent, Inc. Guide system with suction
US10376416B2 (en) 2009-03-31 2019-08-13 Acclarent, Inc. System and method for treatment of non-ventilating middle ear by providing a gas pathway through the nasopharynx
US8435290B2 (en) 2009-03-31 2013-05-07 Acclarent, Inc. System and method for treatment of non-ventilating middle ear by providing a gas pathway through the nasopharynx
US9072626B2 (en) 2009-03-31 2015-07-07 Acclarent, Inc. System and method for treatment of non-ventilating middle ear by providing a gas pathway through the nasopharynx
US9636258B2 (en) 2009-03-31 2017-05-02 Acclarent, Inc. System and method for treatment of non-ventilating middle ear by providing a gas pathway through the nasopharynx
US9155492B2 (en) 2010-09-24 2015-10-13 Acclarent, Inc. Sinus illumination lightwire device
WO2012085195A1 (en) 2010-12-23 2012-06-28 Solvay Sa Environmental friendly purification of an organic solution of etfbo
US10349971B2 (en) 2011-06-29 2019-07-16 CARDINAL HEALTH SWITZERLAND 515 GmbH System and method for dilating and adjusting flexibility in a guiding device
US10524869B2 (en) 2013-03-15 2020-01-07 Acclarent, Inc. Apparatus and method for treatment of ethmoid sinusitis
US9433437B2 (en) 2013-03-15 2016-09-06 Acclarent, Inc. Apparatus and method for treatment of ethmoid sinusitis
US9629684B2 (en) 2013-03-15 2017-04-25 Acclarent, Inc. Apparatus and method for treatment of ethmoid sinusitis
WO2015004040A1 (en) 2013-07-09 2015-01-15 Bayer Cropscience Ag Use of selected pyridone carboxamides or salts thereof as active substances against abiotic plant stress
WO2016096942A1 (en) 2014-12-18 2016-06-23 Bayer Cropscience Aktiengesellschaft Use of selected pyridone carboxamides or salts thereof as active substances against abiotic plant stress

Also Published As

Publication number Publication date
GB9619011D0 (en) 1996-10-23

Similar Documents

Publication Publication Date Title
GB2305174A (en) Chemical process
US4758667A (en) Process for the preparation of 2-(imidazolin-2-yl)-3-pyridine- and -3-quinolinecarboxylic acids
CN115286514B (en) Preparation method of 4' -chloro-2-aminobiphenyl sulfate
JP3452081B2 (en) Fluoro-trifluoromethylbenzoic acid derivatives
JP2001081065A (en) Method for producing [bis-(trifluoromethyl)-phenyl]- acetic acid, its alkyl ester and dialkyl bis-(trifluoromethyl)-phenyl]-malonate
KR100585407B1 (en) Process and intermediates for the manufacture of pyridine-2,3-dicarboxylate compounds
EP0000301B1 (en) Process for the preparation of thieno(2,3-c) and thieno(3,2-c) pyridines
JP3378745B2 (en) Method for producing 4-acylamino-2,2,6,6-tetramethylpiperidine
SK8922002A3 (en) Method for producing 4-(heteroaryl-methyl)-halogen-1(2h)- phthalazinones
EP1064265B1 (en) Synthesis of 3-amino-2-chloro-4-methylpyridine from malononitrile and acetone
US5017705A (en) Production of 3,5,6-trichloropyridin-2 ol and novel intermediates thereof
US6639079B1 (en) Chemical process
EP0638065B1 (en) A process for the preparation of 3- and/or 5-substituted anthranilic acids
JPH0753711B2 (en) Novel pyrrolinones and their production method
JP2816855B2 (en) Process for producing pyridine-2,3-dicarboxylic acid derivative
JP2804559B2 (en) Method for producing 2-chloro-5-chloromethylpyridine
US5252739A (en) Process for preparing pyridine-2,3-dicarboxylic acid compounds
JP2002363161A (en) Method for producing terpyridine
US4139710A (en) Preparation of hexahydroindazolones
JP3869531B2 (en) Production method of biphenyl derivatives
JP4251508B2 (en) Method for producing acid chloride compound
JP2864653B2 (en) Method for producing 2-hydroxynicotinic acid derivative
NL7905372A (en) PROCESS FOR PREPARING A CYCLOPROPANE NITRILE.
JPH093017A (en) N-substituted cis-n-propenylacetamide and its production
US4914243A (en) Production of 2-alkoxy or aryl(lower)alkoxy-6-methoxy-1-naphthalenecarboxaldehyde

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)